Table 2.

Changes in Vascular Lesions Before and After Treatment of Takayasu Arteritis and Giant Cell Arteritis

	Before Treatment	After Treatment	P
Wall thickening
Total, n = 51, median (IQR)	6 (4-13)	2 (0-5)	<.0001
TAK, n = 24, median (IQR)	8 (5-12.5)	4 (2-7)	.01
GCA, n = 27, median (IQR)	5 (3-15)	1 (0-3)	<.0001
Wall enhancement
Total, n = 51, median (IQR)	4 (2-8)	0 (0-2)	<.0001
TAK, n = 24, median (IQR)	3 (2-8)	1 (0-4)	.005
GCA, n = 27, median (IQR)	5 (1-9)	0 (0-0)	<.0001
Acute-phase findings
Total, n = 51, median (IQR)	11 (6-20)	2 (0-8)	<.0001
TAK, n = 24, median (IQR)	11.5 (6-20)	6.5 (2-10.5)	.003
GCA, n = 27, median (IQR)	9 (4-25)	1 (0-4)	<.0001
Stenosis, occlusion
Total, n = 51, median (IQR)	0 (0-2)	0 (0-2)	.475
TAK, n = 24, median (IQR)	1 (0-2.7)	2 (0-3)	.661
GCA, n = 27, median (IQR)	0 (0-0)	0 (0-1)	.499
Dilatation, aneurysm
Total, n = 51, median (IQR)	0 (0-0)	0 (0-0)	.167
TAK, n = 24, median (IQR)	0 (0-0)	0 (0-0)	.334
GCA, n = 27, median (IQR)	0 (0-0)	0 (0-0)	.317
Calcification
Total, n = 51, median (IQR)	1 (0-5)	0 (0-5)	.115
TAK, n = 24, median (IQR)	0 (0-0)	0 (0-0)	.891
GCA, n = 27, median (IQR)	4 (2-7)	4 (2-7)	.066
Chronic-phase findings
Total, n = 51, median (IQR)	3 (1-6)	4 (2-6)	.965
TAK, n = 24, median (IQR)	1.5 (0-3.7)	2 (0-4)	.325
GCA, n = 27, median (IQR)	5 (3-9)	6 (4-9)	.34

Data are analyzed using the Wilcoxon signed-rank test. Acute-phase findings include a combination of wall thickening and contrast enhancement of the vascular wall. Chronic-phase findings include a combination of stenosis, occlusion, dilatation, aneurysm, and calcification. The values are the median sums of the semi-quantitatively assessed scores for all 21 vessels.

GCA, giant cell arteritis; IQR, interquartile range; TAK, Takayasu arteritis.